Target intelligence / Profile preview

Caveolin-3 (Cav-3)

Target
Cav-3
Molecular classification
Other, Membrane scaffolding protein, Caveolin family protein
01

Overview

Caveolin-3 is a membrane-associated scaffolding protein and the principal structural component of caveolae (small invaginations in the plasma membrane) specific to muscle tissue, particularly cardiac and skeletal muscle[1][3][4]. It is encoded by the CAV3 gene and is 151 amino acids in length. Caveolin-3 organizes and supports various signaling complexes, regulates ion channels (such as sodium channels critical for cardiac rhythm), and maintains sarcolemmal stability and muscle cell homeostasis. Mutations in CAV3 disrupt caveolae formation and have been linked to a spectrum of muscle diseases, including limb-girdle muscular dystrophy type 1C, distal myopathy, rippling muscle disease, hyperCKemia, and various cardiomyopathies[2][3][4]. Caveolin-3 also plays a role in signaling pathways relevant to cellular protection and stress response in cardiac muscle[1].

Other names
CAV3caveolin betaM-caveolinmuscle caveolincaveolin beta-1LGMD-1C protein
02

Mechanism of action

Stabilization/restoration of caveolae structure; Regulation of associated signaling pathways (PI3K/Akt/eNOS/PKC); Modulation of sarcolemmal membrane stability

03

Biological functions

Plasma membrane organization and curvatureSignal transductionMuscle cell homeostasisVesicular traffickingRegulation of muscle contractionScaffolding for ion channels and signaling complexes
04

Disease associations

Muscular dystrophy (Limb-girdle muscular dystrophy type 1C)Distal myopathyHyperCKemiaRippling muscle diseaseLong QT syndromeFamilial hypertrophic cardiomyopathyCardiovascular disease (implicated in cardiomyopathies)
05

Safety considerations

Therapeutic challenges include off-target effects due to widespread role in cell membrane organizationpotential for muscle or heart dysfunctionarrhythmiasexacerbation of underlying muscle disease
06

Interacting drugs

None approved or directly targeting Caveolin-3; research ongoing into small molecules affecting caveolin pathway, but no named drugs currently in clinical use targeting Cav-3 directly
07

Biomarkers

Elevated creatine kinase (CK) (for hyperCKemia)caveolin-3 protein expression/mutations for diagnosis of muscular dystrophies and related myopathies

Beyond the preview

Go deeper on Caveolin-3 (Cav-3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caveolin-3 (Cav-3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call